Gericke has launched the GFS Gen3, a next‑generation continuous manufacturing platform designed to streamline pharmaceutical production from clinical development through to commercial scale.
The system addresses industry demands for faster development cycles, improved containment and simplified process transitions. GFS Gen3 enables manufacturers to maintain a consistent process philosophy across all stages of oral solid‑dose (OSD) formulation.
By reducing reliance on multiple batch systems, the platform minimises re‑qualification work, shortens development timelines and lowers operational risk.
Gericke highlights that the system’s modular design supports evolving regulatory and containment requirements, while maintaining high levels of precision and reliability.
The GFS Gen3 platform reflects a shift towards continuous processing in the pharmaceutical sector, offering improved efficiency and reduced disruption across the product lifecycle.
Gericke introduces GFS Gen3 for advanced pharmaceutical manufacturing
